company background image
LCTX logo

Lineage Cell Therapeutics NYSEAM:LCTX Stock Report

Last Price

US$1.40

Market Cap

US$263.9m

7D

14.8%

1Y

-2.8%

Updated

27 Mar, 2024

Data

Company Financials +

Lineage Cell Therapeutics, Inc.

NYSEAM:LCTX Stock Report

Market Cap: US$263.9m

LCTX Stock Overview

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally.

LCTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Lineage Cell Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lineage Cell Therapeutics
Historical stock prices
Current Share PriceUS$1.40
52 Week HighUS$1.57
52 Week LowUS$0.84
Beta1.27
1 Month Change34.62%
3 Month Change21.74%
1 Year Change-2.78%
3 Year Change-40.43%
5 Year Change4.48%
Change since IPO-59.02%

Recent News & Updates

Recent updates

What Type Of Shareholders Own The Most Number of Lineage Cell Therapeutics, Inc. (NYSEMKT:LCTX) Shares?

Feb 17
What Type Of Shareholders Own The Most Number of Lineage Cell Therapeutics, Inc. (NYSEMKT:LCTX) Shares?

If You Had Bought Lineage Cell Therapeutics (NYSEMKT:LCTX) Stock A Year Ago, You Could Pocket A 129% Gain Today

Dec 26
If You Had Bought Lineage Cell Therapeutics (NYSEMKT:LCTX) Stock A Year Ago, You Could Pocket A 129% Gain Today

Shareholder Returns

LCTXUS BiotechsUS Market
7D14.8%0.9%0.4%
1Y-2.8%10.3%28.8%

Return vs Industry: LCTX underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: LCTX underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is LCTX's price volatile compared to industry and market?
LCTX volatility
LCTX Average Weekly Movement12.1%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: LCTX's share price has been volatile over the past 3 months.

Volatility Over Time: LCTX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199072Brian Culleyhttps://www.lineagecell.com

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.

Lineage Cell Therapeutics, Inc. Fundamentals Summary

How do Lineage Cell Therapeutics's earnings and revenue compare to its market cap?
LCTX fundamental statistics
Market capUS$263.95m
Earnings (TTM)-US$21.49m
Revenue (TTM)US$8.95m

29.5x

P/S Ratio

-12.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LCTX income statement (TTM)
RevenueUS$8.95m
Cost of RevenueUS$671.00k
Gross ProfitUS$8.27m
Other ExpensesUS$29.76m
Earnings-US$21.49m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.11
Gross Margin92.50%
Net Profit Margin-240.20%
Debt/Equity Ratio0%

How did LCTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.